In the latest trading session, Gilead Sciences (GILD) closed at $110.67, marking a +2.83% move from the previous day.

Gilead's top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a phase 3 trial. The drug, an apoptosis signal-regulating ...

Grooves of Houston, a clubstaurant specializing in breakfast and brunch staples and kickback vibes, is hosting hours of line ...